22 results about "Caplet Dosage Form" patented technology

The present disclosure relates to suspension-based pharmaceutical formulations for cold and flu medications, and more specifically to high-concentration suspension formulations and soft gel capsule dosage forms having reduced size, as well as methods of preparing the suspension formulations and soft gel capsules thereof.

The invention provides a candesartan cilexetil capsule and a preparation method thereof, and the candesartan cilexetil capsule is characterized in that each capsule contains candesartan cilexetil, lactose, corn starch, hydroxypropyl cellulose, carboxymethyl cellulose calcium, polyethylene glycol 8000 and magnesium stearate. According to the candesartan cilexetil capsule provided by the invention, the problem of stability of candesartan cilexetil is solved, the possibility of crystal transformation of common tablets in a tabletting process is reduced, and the characteristic dissolution curve of a final product is similar to that of a reference preparation; the preparation method is simple in process route, the fluidized bed one-step granulation method enables the loss to be less, the product yield is higher, and the industrial mass production cost is reduced.

A transient oil-in-simethicone emulsion for oral administration wherein 5 simethicone is present from 50% to 80% by weight of the emulsion. Also described is the process for the preparation of the transient oil-in-simethicone emulsion and capsule dosage form.

The invention discloses a defoaming agent adaptive to a digestive tract environment, and a preparation method and application thereof, and relates to the technical field of digestive tract examination assistance. The defoaming agent comprises simethicone, hyaluronidase, bromelain and sodium bicarbonate, and the preparation form is a capsule in which a quick-release drug-loading unit and an enteric drug-loading unit are mixed. The preparation method comprises the following steps: preparing the quick-release drug-loading unit, preparing the enteric drug-loading unit, and mixing and encapsulating. The defoaming agent is orally taken 25-35 minutes before gastroscopy, a closed loop of gastric acid neutralization, thick mucus degradation and foam removal effects can be formed, the problem of poor defoaming caused by mucus wrapping foam is solved, the field of view in the stomach is optimized, and the accuracy of stomach disease diagnosis is guaranteed.

The present disclosure relates to compositions comprising coenzyme Q10 and a water soluble excipient, and methods for treating coenzyme Q10 deficiency in a subject, including oral administration of the composition. The composition can be in a solid or liquid dosage form, such as a ball, a granule, a tablet, a capsule, an oral solution and a soft capsule, and is used for oral administration. The composition may comprise coenzyme Q10 and a binder mixture coated on a tablet core, wherein the tablet core comprises a sugar, microcrystalline cellulose, or a mixture thereof. The composition is an immediate release formulation having high solubility in an aqueous medium.

The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

The present invention relates to a pharmaceutical composition comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizers in the form: A) an aqueous solution for intravenous administration comprising a sodium salt or lysine salt of ibuprofen, acetaminophen and preferably one or more cyclodextrins; or B) an aqueous solution for intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins; or C) a composition for oral administration comprising acetaminophen and cyclodextrin wherein the composition is in the form of i) an effervescent tablet or effervescent granule, or ii) an oral suspension or syrup or oral solution, or iii) a soft capsule.

The invention discloses an ibrutinib pharmaceutical composition and preparation as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. In order to solve the problems of low bioavailability, large administration dosage, high side effect risk and the like of ibrutinib, the invention provides an ibrutinib pharmaceutical composition and preparation as well as a preparation method and application thereof, the pharmaceutical composition comprises an active substance ibrutinib monolauryl sulfate, a filler, a release regulator and / or other auxiliary materials, the other auxiliary materials comprise at least one of a lubricant, a disintegrating agent and a flow aid; the preparation is a capsule or a tablet. According to the preparation of the ibrutinib monolaurinol sulfate composition prepared by adopting granulation or direct mixing, the bioavailability is greatly improved, and the dosage is greatly reduced under the condition that the blood exposure is basically unchanged; meanwhile, relatively stable blood concentration can be maintained, and the preparation has the advantages of small toxic and side effects, convenience in taking, high bioavailability and the like.

This invention relates to an ionic amphiphilic bioporphyrin, its preparation method, and its application, belonging to the field of pharmaceutical technology. The preparation method of the ionic amphiphilic bioporphyrin of this invention includes the following steps: stirring and reacting heme with an alkaline solution to obtain a dispersion; adding an acidic solution to the obtained dispersion to adjust the pH to 4-11, thereby obtaining the ionic amphiphilic bioporphyrin. This invention combines the ionized modified amphiphilic bioporphyrin with alkaline excipients and prepares it into an enteric-coated capsule dosage form, ensuring its stability in gastric acid. Upon reaching the intestine, it achieves effective release and creates a suitable alkaline microenvironment for the dissolution of ionic heme, thereby improving the solubility of heme derivatives in the intestine and oral uptake efficiency.

The present disclosure relates to suspension-based pharmaceutical formulations for cold and flu medications, and more specifically to high-concentration suspension formulations and soft gel capsule dosage forms having reduced size, as well as methods of preparing the suspension formulations and soft gel capsules thereof.

The invention relates to a cabazitaxel composition and application of the cabazitaxel composition. Embodiments provide a composition comprising cabazitaxel and at least one lipid and / or cougsterol, and / or a cougsterol derivative, and / or sodium cholesterol sulfate, in the form of a tablet or capsule, and administering the composition to a subject.

A rupatifen fumarate capsule and a preparation method therefor. The capsule comprises a capsule shell and contents enclosed by the capsule shell. The capsule has excellent formulation performance and good stability. During preparation and long-term storage, there is no reduction in drug substance content and no significant increase in impurity content. The dissolution rate is fast, and the stability is good, thereby ensuring the quality of the final formulation and the safety and effectiveness of clinical use.

The application discloses a pharmaceutical composition containing abiraterone acetate and a preparation method and application thereof. An excipient of the pharmaceutical composition contains at least one oil phase, at least one emulsifier and at least one co-emulsifier. The pharmaceutical composition can significantly improve bioavailability and stability of a preparation. The pharmaceutical composition can be further prepared into a capsule.

A racanisodamine capsule with high dissolution rate and fast disintegration belongs to the technical field of medicine preparation, and through the innovation of narrow distribution micronization of active ingredients, synergistic compatibility of novel auxiliary materials, capsule type adaptation process and the like, the prepared racanisodamine capsule has the dissolution rate of more than or equal to 95% within 30 min and the accelerated test dissolution rate of more than or equal to 92% within 12 months, the auxiliary materials are plant-derived or degradable ingredients, and the process energy consumption is reduced by more than 20%. The invention expands the dosage form applicable population, further improves the drug effect and safety, is energy-saving and environment-friendly, and conforms to the green pharmaceutical trend.

The present invention relates to a water-soluble film having a mometasone furoate content adjusted to a pH in the range of 3.5 to 5.0. The correspondingly adjusted pH increases the stability of the active ingredient without substantially impairing the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing films of the above type in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can especially be used for treating eosinophilic esophagitis.

This invention belongs to the field of organic synthesis technology and discloses an N-(4-(pyridin-4-yloxy)phenyl)-1,4-dihydropyridazine-3-carboxamide compound, its preparation method, and its applications. The preparation method of the N-(4-(pyridin-4-yloxy)phenyl)-1,4-dihydropyridazine-3-carboxamide compound provided by this invention is simple and easy to implement. The N-(4-(pyridin-4-yloxy)phenyl)-1,4-dihydropyridazine-3-carboxamide compound provided by this invention can be used to prepare drugs for treating ulcerative colitis and can be formulated into injections, tablets, capsules, aerosols, suppositories, films, pellets, ointments, controlled-release agents, sustained-release agents, or nano-formulations.

The invention discloses an oral solid preparation of valsartan. The oral solid preparation comprises a valsartan eutectic compound and pharmaceutically acceptable auxiliary materials, the oral solid preparation comprises tablets, capsules and granules, and the content of the active substance valsartan is 10-320 mg. The valsartan eutectic compound is prepared by forming a supramolecular compound from valsartan and a specific eutectic precursor molecule (such as nicotinamide), loading the supramolecular compound in a pore channel of a mesoporous silica nano-carrier with a high specific surface area in a confinement manner, and modifying the supramolecular compound with a surface stabilizer. According to the method, medicine crystallization is inhibited by utilizing a nano confinement effect, and the medicine exists in an amorphous or molecular-level dispersed high-energy state under the synergistic action of eutectic precursor molecules, so that the dissolution rate and oral absorption efficiency of the medicine are greatly improved. The valsartan preparation is simple in process, good in stability and suitable for industrial production, and the prepared valsartan preparation has excellent in-vitro dissolution rate and in-vivo bioavailability.

The invention relates to an OAB-14 pellet, a pellet capsule and a pellet tablet, which comprise an OAB-14 suspension, a pellet core and a high-molecular polymer, the weight ratio of the OAB-14 to the high-molecular polymer is 4: 1-4: 3, the OAB-14 suspension is added into the high-molecular polymer to prepare a lamination liquid, and the lamination liquid is laminated on the pellet core to prepare the OAB-14 pellet; the OAB-14 suspension comprises OAB-14, a stabilizer and an aqueous solution, and the mass ratio of the OAB-14 to the stabilizer to the aqueous solution is 1: (0.08-16): (1.5-28); the particle size d (0.5) of the OAB-14 is 1 to 1000 nm, and the particle size d (0.9) of the OAB-14 is 2 to 3000 nm. The solubility and fat solubility of the OAB-14 are increased, the purposes of improving bioavailability and penetrating a blood-brain barrier are achieved, and the key problem of OAB-14 patent medicine is solved. The invention further keeps the same treatment effect as the OAB-14 suspension, is convenient to store and carry, and improves the compliance of patients.

The invention belongs to the field of medicines, and particularly relates to a combined medicine for treating thrombosis through synergistic interaction and application of the combined medicine. The invention relates to a pharmaceutical composition, which is characterized in that the pharmaceutical composition comprises 1, 2, 3, 4, 6-pentagalloyl-beta-D-glucose and fumaric acid, and the weight ratio of the 1, 2, 3, 4, 6-pentagalloyl-beta-D-glucose to the fumaric acid is 1: (0.2-5). Researches prove that when fumaric acid and 1, 2, 3, 4, 6-pentagalloyl-beta-D-glucose are combined for use, nerve cell injury caused by glutamic acid and thrombin can be synergistically protected, thrombosis formation can be resisted, activation of MKK3, MKK6 and p38 in a p38MAPK signal channel can be inhibited, and a p38-MKK3 axis can be blocked. The invention can be used for targeted drugs for treating thrombosis. And the compound can be conveniently prepared into solid preparation medicines such as tablets, capsules, solid dispersions, suspensions or granules together with a carrier.

The present application provides a kind of isosorbide mononitrate sustained-release capsules and its preparation method, the isosorbide mononitrate sustained-release capsule of the present application, characterized in that, the drug loading layer, sustained-release layer, immediate-release layer and protective layer of the isosorbide mononitrate sustained-release capsule are respectively coated by fluidized bed granulation coating machine.The granular preparation has good stability, small side effect;The preparation process of the isosorbide mononitrate sustained-release capsule of the present application is simple, the equipment is simple and easy to operate, the labor intensity is small, and it is economic and safe.At the same time, the prescription and preparation method are more economical, and are suitable for industrial production.

The invention belongs to the technical field of medicines for treating myocardial hypertrophy, and discloses a pharmaceutical composition containing benzoyl mesaconitine and paeoniflorin and application thereof.The pharmaceutical composition is characterized by comprising benzoyl mesaconitine or pharmaceutical salt thereof and paeoniflorin or pharmaceutical salt thereof as active ingredients, the molar ratio of benzoyl mesaconitine to paeoniflorin is 1: 1000-1000: 1, preferably 5: 1000, and the molar ratio of benzoyl mesaconitine to paeoniflorin is 1: 1000-1000. Cell experiment results show that the composition can play a remarkable synergistic effect in the process of intervening angiotensin II induced myocardial cell hypertrophy, the effect of the composition is superior to that of a single component, the oxidative stress level of cells can be effectively relieved, and the curative effect of the composition is improved. The invention provides a new generation of medicine scheme with definite components and remarkable effect for clinical treatment of myocardial hypertrophy, can be used for preparing various dosage forms such as tablets, capsules and injections, and has important clinical transformation value and application prospect.